CTMC - a joint venture between Resilience + MD Anderson Cancer Center

Tyler Menichiello of Bioprocess Online will host our CEO, Jason Bock, along with Emily English and Tal Salz, to debate the pros and cons of centralized vs. point of care manufacturing of CAR-Ts. Join this timely discussion on Tuesday, 27 August at 11 EDT. https://lnkd.in/g4nBgMis 

🧬 Register for free for the CIMT #Cancer Cell Therapy Summit hosted by the Champalimaud Foundation in Lisbon ☀ , September 18-19! Key topics will cover 👀 : - Innovative cellular therapies for #solidtumours; - The limits and possibilities of engineered #immune cells; - The gap between academic and #biotech / #pharma research; - Challenges in conducting safe and relevant phase I/II #clinicaltrials 👉 Learn more and register here: https://lnkd.in/e7uYQpiK Learn and network with leading researchers and developers 👇 : Prof Dr Christian Blank / Marie Arsenian Henriksson / Sebastian Klobuch / Davide Bedognetti / Cécile Alanio / Mirjam Heemskerk / Tal Danino / Lei (Stanley) Qi / Andreas Mackensen / Judith Kroep / Sebastian Kobold / Mark Yarmarkovich, PhD / Jason Bock

Happy National Intern Day! In May, Natalie Gómez, Di Duong, Vikram Chavare, and Malak Elazzazi joined CTMC as interns in our Process Development, Analytical Development, and Viral Vector departments. They have been wonderful students and great contributors to our teams. #celltherapy

At CTMC, we have expertise in multiple modalities including CAR-T. Several terrific members of our process development and tech ops teams are featured below at our recent 2nd Anniversary party. We continue to collaborate with past and new CAR-T partners to optimize processes and analytics with the goal of accelerating timelines to reach patients faster. #celltherapy #CARTmanufacturing #CART #tcells #bloodcancer #endcancer

We're #hiring a new QA Specialist II in Houston, Texas. Apply today or share this post with your network.

Several decades ago, a brilliant (and DETERMINED) scientist discovered that a patient's tumor infiltrating lymphocytes could attack cancerous cells and shrink tumors. This year the FDA approved the first TIL therapy, Amtagvi, to treat metastatic melanoma. Clinical trials are showing promise in next-generation TIL therapy treating other aggressive solid cancers that have few treatment options. Our team of TIL experts continues to improve our TIL platform and manufacturing processes while working side-by-side our co-development partners to bring TIL therapies to patients. Thank you to this team for your continued dedication. #lifesciences #celltherapy #TILtherapy #StevenRosenberg #endcancer

We're #hiring a new Associate III, Manufacturing in Houston, Texas. Apply today or share this post with your network.

CTMC's 2-Year Birthday Party...   CTMC+ recently celebrated our 2nd anniversary since spinning off from MD Anderson Cancer Center. It's been a busy and productive two years: *cleared six INDs in 18 months with no delays *manufactured (and tested) over 160 GMP batches across 9 clinical programs *renovated and validated four new cleanrooms to bring our total up to 14 *implemented five IT systems to improve productivity, safety, and collaboration with plan to be 100% digital by end of Year 3 *and, so much more. We have a dedicated and talented team of industry and academic experts working collaboratively with our partners to bring life-saving cell therapies to patients faster than ever. Year 3 is going to be even better! #biotech #celltherapy #innovation #venturecapital #TILtherapy #celltherapymanufacturing #endcancer

SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia)'s 2024 @Philly Cell and Gene Therapy Annual Conference was well-attended by over 500 guests. Jason Bock was honored to give the keynote address: "Accelerating the Cell Therapy Transformation". The cell therapy field could develop through silos...or, accelerate development through intentional, integrated partnerships. CTMC champions collaboration and partnerships so we can bring life-saving cell therapies to patients faster.

Ori Biotech introduced IRO to a packed audience at ISCT, International Society for Cell & Gene Therapy yesterday. In his presentation, "What Got Us Here, Won't Get Us There," Jason Bock reflected on how challenges with variable starting material, variable processes, and variable analytics will continue to hold the cell therapy field back. Automation is one key step that will help accelerate the process to improve access. CTMC is thrilled to have collaborated on this project with the terrific team at Ori and to share such positive data from our comparability studies. #ISCT24 #biotech #celltherapy #celltherapymanufacturing #endcancer Jason C. Foster